Assessing cardiovascular and cerebrovascular events in COPD patients using different inhalers
Official title: Multinational Database Cohort Study to Assess Adverse Cardiovascular and Cerebrovascular Outcomes in Patients With COPD Initiating a Fixed Triple Therapy Containing BDP, FF and GB Administered Via DPI Compared to pMDI
Run by Chiesi Farmaceutici S.p.A. · NCT05652439 · Data updated 2026-11-12
This study is trying to see if using a Dry Powder Inhaler is safer than a Metered Dose Inhaler for older adults with COPD by looking at heart and brain-related health issues.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 40 Years and up |
| Sex | All |
| Enrollment | 25000 (estimated) |
| Sponsor | Chiesi Farmaceutici S.p.A. Industry-sponsored |
| Locations | 1 site (London) |
| Status | Recruiting |
| Started | December 2, 2022 |
| Main results expected | March 2027 |
| Study ends | March 2027 |
| Registry record updated | October 22, 2026 |
| Trial ID | NCT05652439 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are COPD patients aged 40 and older who are new users of inhaled fixed triple therapy.
✕Probably not a fit
Patients who have recently used any form of triple therapy or have had cardiovascular hospitalization in the past 30 days may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the incidence of adverse cardiovascular and cerebrovascular events in patients with chronic obstructive pulmonary disease (COPD) who are new users of inhaled fixed triple therapy. It compares the safety profile of the Dry Powder Inhaler (DPI) against the pressurized Metered Dose Inhaler (pMDI). Data will be collected retrospectively from various European health databases, focusing on patients aged 40 and older who have been diagnosed with COPD. The study will track outcomes from the initiation of therapy until certain predefined endpoints.
Why it matters
Potential benefit: If successful, this study could provide insights into the safety of different inhaler devices for COPD patients, potentially guiding treatment choices.
How similar studies have gone: Other studies have explored similar safety assessments in COPD treatments, but this specific comparison of DPI and pMDI is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed with COPD * 40 years or older * Availability of baseline information for a minimum of 12 months before the index date * New users of single inhaler triple therapy BDP/FF/GB via DPI or pMDI Exclusion Criteria: * Single or multi-inhaler triple therapy in the previous 90 days before the index date * Prescription of BDP/FF/GP administered via pMDI or DPI or any other single inhaler triple therapy in addition to a study drug on the index date. * Hospitalization due to cardiovascular causes in the previous 30 days before the index date.
Where it's running
-
Clinical Practice Research Datalink (CPRD)
London, United Kingdom Recruiting
Study contacts
- Principal investigator: Fabian Hoti — IQVIA Pty Ltd
- Study coordinator: Clinical Trial Info
- Email: clinicaltrials_info@chiesi.com
- Phone: +3905212791
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Flutter therapy added to chest physiotherapy after CABG in COPD patients
This study tests whether adding Flutter therapy to standard chest physiotherapy helps post-CABG patients with mild-to-moderate COPD improve breathing more than chest physiotherapy alone.
-
TPB-based cadence exercise and breathing training for COPD patients
A TPB-based program tests whether breathing training, cadence-guided walking, or both can improve lung function, exercise capacity, and quality of life in adults with COPD.
-
See how dynamic chest X-rays relate to COPD patterns and progression risk
This study looks at existing dynamic chest radiography data to see if new imaging measurements can identify COPD patterns, gauge severity, and predict who may experience faster progression.
-
Personalized mobile app warnings to reduce COPD flares
A personalized mobile app tests whether providing temperature-related risk warnings and protective tips, in addition to usual COPD care, can lower COPD flare-ups over 12 months.
-
CLEAR model to predict when people with severe COPD can be taken off ventilatory support
This project will see if the CLEAR model can predict which adults with severe COPD on invasive or non‑invasive ventilation can be safely taken off ventilatory support.
-
Long-term safety of Tozorakimab in COPD patients with prior exacerbations
This study tests two long-term dosing regimens of tozorakimab in people with COPD who have a history of flare-ups and who completed earlier studies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.